|
rs121913355
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of therapy with BRAF inhibitors and a promising therapeutic approach may be with nab-paclitaxel.
|
26070258 |
2015 |
|
rs121913378
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
|
25382067 |
2015 |
|
rs121913364
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.
|
24933606 |
2014 |
|
rs121913366
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Trametinib has antitumour activity in patients with BRAF K601E and L597Q mutation-positive metastatic melanoma.
|
24933606 |
2014 |
|
rs121913368
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Tumors from patients with BRAF wild-type (WT), V600E (class I), and L597S (class II) metastatic melanoma were used to generate patient-derived xenografts (PDX).
|
29903896 |
2018 |
|
rs121913368
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A patient with BRAF(L597S) mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor, TAK-733.
|
22798288 |
2012 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, has demonstrated great promise in treating metastatic melanoma associated with BRAF V600E and V600K mutations; however, it also is highly associated with cutaneous adverse events (AEs).
|
30489553 |
2018 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma.
|
28738051 |
2017 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
To review and summarize data on cobimetinib, which was approved by the US Food and Drug Administration (FDA) in November 2015 for use in combination with vemurafenib for unresectable or metastatic melanoma with a BRAFV600E or V600K mutation.
|
27701080 |
2017 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone.
|
26433819 |
2015 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma.
|
26037941 |
2015 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF inhibitor activity in V600R metastatic melanoma.
|
23237741 |
2013 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The aim of the present study was to investigate the frequency of the less common p.Val600Lys (V600K) mutation in metastatic melanoma from a high incidence region.
|
22614711 |
2012 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
|
23051966 |
2012 |
|
rs121913227
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
|
22535154 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Currently, several targeted therapy regimens are approved as first-line treatment in V600E/K-mutant advanced and metastatic melanoma.
|
31305324 |
2020 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Currently, several targeted therapy regimens are approved as first-line treatment in V600E/K-mutant advanced and metastatic melanoma.
|
31305324 |
2020 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In contrast to patients with BRAF V600E-mutated metastatic melanoma, only 5% of patients with BRAF V600E-mutated mCRC responded to BRAF inhibitor monotherapy in an early-phase trial.
|
31219603 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF/MEK inhibition is a standard of care for patients with <i>BRAF</i> V600E/K-mutated metastatic melanoma.
|
31580757 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we describe a patient with BRAF-V600E-positive metastatic melanoma who was sequentially treated with BRAF/MEK inhibitors (dabrafenib/trametinib) and checkpoint inhibitor immunotherapy (nivolumab, followed by pembrolizumab).
|
31082388 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although vemurafenib has been shown to improve the overall survival of patients with metastatic melanoma harboring the BRAF V600E mutation, its efficacy is often hampered by drug resistance acquired within a relatively short period through several distinct mechanisms.
|
30920401 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 75-year-old male developed a swelling in his left inguinal region and was diagnosed with a metastatic melanoma, which was found to harbor a BRAF V600E mutation.
|
31260118 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe peripheral blood smear, bone marrow morphology, histopathology, immunohistochemistry, including BRAF V600E, and molecular testing results of patients with metastatic melanoma to the bone marrow.
|
31112348 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In contrast to metastatic melanoma, BRAF inhibition alone or in combination with mitogen-activated protein kinase kinase (MEK) inhibitors has shown little utility in the treatment of BRAF V600E-mutant mCRC.
|
31840683 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31-68 years of age) were included.
|
29324592 |
2019 |